Shares of BioNTech on Wednesday reached a new low for the year. However, it turned out to be a false signal. On Thursday, the paper could even grow significantly. In U.S. trading, the paper strengthened about seven percent to $ 132.29. A biotech company based in Mainz has also benefited from the good news about the future pipeline.
BioNTech has announced that the European Medicines Agency (EMA) has awarded the PRIME (Priority Medicines) label to BioNTech’s proprietary product candidate BNT211 as a third-line treatment for advanced testicular germ cell tumors. BNT211 is a new therapeutic approach that combines BioNTech’s two innovative proprietary drug candidates in synergistic treatment: autologous CAR-T cell therapy targeting the oncofetal antigen claudin-6 (CLDN6) and CLDN6-encoding CAR-T RNA that enhances CARVac RNA), it is stated in the announcement.
The product candidate is currently being evaluated in an ongoing phase 1/2 study (NCT04503278; 2019-004323-20) aimed at assessing safety and early signs of efficacy in patients who have been severely previously treated with relapse or refractory advanced solid tumors.
“Patients with recurrent or refractory testicular cancer had a poor overall prognosis and only limited treatment options. PRIME status emphasizes the potential of our approach in this indication of great unmet medical needs, ”said prof. Özlem Türeci, co-founder and Chief Medical Officer at BioNTech. “We believe we can stimulate and expand programmable T cells by combining them with mRNA vaccines in a single treatment regimen. This approach could allow us to develop highly effective precision immunotherapies. ”
At BioNTech, the future pipeline is increasingly coming into focus. If further positive news follows, the stock should quickly regain momentum. There could be a new impetus next week. On Wednesday, June 29, BioNTech will host the first edition of the “Innovation Series”. The virtual event will provide up-to-date information on BioNTech’s progress in the clinical evaluation of its additional candidates, as well as a comprehensive look at the scientific and technological innovations of the company’s research driver. You can read the current share estimate in the new issue 26/2022 of AKTIONÄR, which you here can download.
(with material from dpa-AFX)
Conflict of interest notice:
The CEO and majority owner of the publisher Börsenmedien AG, Mr. Bernd Förtsch, has taken direct and indirect views on the following financial instruments mentioned in the publication or related derivatives that may benefit from any price development arising from the publication: BioNTech.
The author has direct views on the following financial instruments mentioned in the publication or related derivatives that may benefit from any price development arising from the publication: BioNTech.
Conflict of Interest Notice: BioNTech shares are located in the SHAREHOLDERS depot.